| Literature DB >> 30675268 |
Yanling Xu1,2, Zhenzhong Su1, Junyao Li1, Qi Wang1, Guangping Meng1, Yu Zhang2, Wen Yang2, Jie Zhang1, Peng Gao1.
Abstract
Lung cancer remains one of the leading causes of cancer-associated mortality in the world. Lung carcinogenesis is frequently associated with deletions or the loss of heterozygosity at the critical chromosomal region 3p21.3, where RNA-binding protein 5 (RBM5) is localized. RBM5 regulates cell growth, cell cycle progression and apoptosis in cell homeostasis. In the lungs, altered RBM5 protein expression leads to alterations in cell growth and apoptosis, with subsequent lung pathogenesis and varied responses to treatment in patients with lung cancer. Detection of RBM5 expression may be a tumor marker for diagnosis, prediction and treatment response in lung cancer, and may be developed as a potential therapeutic target for drug resistant lung cancer. This review discusses the most recent progress on the role of RBM5 in lung cancer.Entities:
Keywords: RNA-binding motif 5; biomarker; lung cancer; molecular target therapy
Year: 2018 PMID: 30675268 PMCID: PMC6341905 DOI: 10.3892/ol.2018.9818
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967